TFC Therapeutics
Pre Seed Round in 2023
TFC Therapeutics is a biotechnology company focused on creating innovative biologics aimed at addressing critical factors in cancer recurrence and metastasis. The company develops technology that employs monoclonal antibodies designed to specifically bind to receptors on tumor-initiating cells, known as TMH cells. This targeted approach activates the immune system to effectively destroy these cells, offering new treatment possibilities for cancer within the healthcare sector. Through its research and development efforts, TFC Therapeutics seeks to contribute significantly to advancements in cancer therapy.
Stablix Therapeutics is a biotechnology company specializing in Targeted Protein Stabilization (TPS). It develops heterobifunctional small molecules that recruit deubiquitinase enzymes to stabilize or enhance targeted proteins, focusing on treating rare diseases, cancer, and immunological disorders.
C2i Genomics
Series B in 2021
C2i Genomics, Inc. is a biotechnology company that specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-resection cancer patients. Founded in 2019 and based in New York with a research and development center in Haifa, Israel, the company offers liquid biopsy services that detect subtle changes in tumor DNA to assess cancer recurrence and progression. Its technology supports a bio-platform approach applicable across various cancer types, enhancing the effectiveness of treatments such as surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enabling healthcare professionals to monitor treatment responses and detect potential treatment failures or disease recurrence more effectively than traditional methods.
TerMir is an innovative AgTech company focused on developing solutions for significant agronomic and environmental challenges. The company specializes in creating antibacterial agents aimed at treating invasive citrus greening disease, a serious threat to citrus crops, as well as biological herbicides to control weed growth. By providing these pioneering products, TerMir enables farmers to enhance crop production and address critical issues in agriculture effectively.
Cradle Genomics
Series A in 2019
Cradle Genomics, Inc. is a biotechnology company focused on advancing non-invasive prenatal testing (NIPT) through comprehensive fetal genetic analysis and pregnancy health screening solutions. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company aims to enhance the knowledge available to expectant parents. Cradle Genomics specializes in analyzing fetal cells collected during the first trimester, allowing for rapid and safe testing that poses no risk to the mother or developing fetus. By providing critical insights early in pregnancy, Cradle Genomics empowers women to make informed health decisions.
Strand Therapeutics
Seed Round in 2019
Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.
Halio specializes in manufacturing advanced smart-tinting glass that dynamically responds to changing light conditions. Their innovative technology enables windows, walls, and skylights to transition from clear to tinted or dark automatically or on command, enhancing comfort, efficiency, and aesthetics for buildings and homes.
Avidity Biosciences
Series B in 2018
Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.
KSQ Therapeutics
Series C in 2018
KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.
KSQ Therapeutics
Series B in 2017
KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.
Aitia
Venture Round in 2017
Aitia is a leader in the application of Causal AI and Digital Twins focused on advancing drug discovery and development. The company utilizes machine learning and the convergence of multi-omic patient data to create Digital Twins that replicate the biological mechanisms of diseases. This innovative approach is particularly impactful in areas such as oncology, neurodegenerative disorders, and immunology. Aitia's Gemini Digital Twins are currently employed to identify novel therapies and expedite research and development in various conditions, including multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with additional projects underway. The company collaborates with several prominent pharmaceutical firms, academic institutions, medical societies, and patient advocacy groups worldwide, thereby enhancing the potential for breakthroughs in medicine.
Arbor Biotechnologies
Series A in 2017
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.
Frequency Therapeutics
Series A in 2017
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.
GenePeeks
Series B in 2017
GenePeeks, Inc. is a genetic information company headquartered in New York, New York, that focuses on reducing the risk of heritable diseases through innovative technology. Incorporated in 2009, the company has developed a proprietary software platform that digitally combines the DNA of prospective parents to simulate genetic recombination and reduction. This process generates a comprehensive analysis of potential future children’s genetic profiles, identifying disease risks that existing pre-conception screening methods may overlook. By utilizing Next-Gen sequencing data, GenePeeks creates tens of thousands of virtual genomes, enabling healthcare providers to assess high-risk genetic matches and enhance their understanding of clinically relevant genotypes and variants. The company's mission is to help families safeguard the health of future generations by providing deeper genetic insights.
AgriMetis
Series B in 2017
AgriMetis, LLC is a company specializing in the research, development, and production of sustainable crop protection products. Founded in 2014, it is headquartered in Lutherville, Maryland, with additional facilities in Research Triangle Park, North Carolina, and Gaithersburg, Maryland. AgriMetis focuses on creating natural product-derived compounds that serve as fungicides, herbicides, insecticides, and nematicides, aimed at protecting crops from weeds, fungal diseases, and insect pests. By providing innovative and efficient solutions for crop protection, the company enables farmers to utilize safe and cost-effective options that contribute to sustainable agricultural practices.
Blackthorn Therapeutics
Series A in 2016
Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.
OncoResponse
Series A in 2016
OncoResponse is an immuno‑oncology biotechnology company that uses a proprietary human antibody platform to discover novel targets and develop fully human monoclonal antibodies for cancer treatment. By interrogating the adaptive immune system of patients who respond exceptionally well to checkpoint inhibition, the company identifies genuine human antibodies against high‑value targets linked with immunosuppressive myeloid biology. Its pipeline aims to alleviate tumor‑microenvironment immunosuppression and enhance immune activation, converting cold tumors into hot ones and providing new therapeutic options for patients.
IDEAYA Biosciences
Series A in 2016
IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.
Aitia is a leader in the application of Causal AI and Digital Twins focused on advancing drug discovery and development. The company utilizes machine learning and the convergence of multi-omic patient data to create Digital Twins that replicate the biological mechanisms of diseases. This innovative approach is particularly impactful in areas such as oncology, neurodegenerative disorders, and immunology. Aitia's Gemini Digital Twins are currently employed to identify novel therapies and expedite research and development in various conditions, including multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with additional projects underway. The company collaborates with several prominent pharmaceutical firms, academic institutions, medical societies, and patient advocacy groups worldwide, thereby enhancing the potential for breakthroughs in medicine.
Faraday Pharmaceuticals
Series A in 2014
Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.
Cydan
Venture Round in 2013
Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The company identifies and de-risks compounds that hold therapeutic and commercial potential, employing a rigorous process to generate data that supports both development pathways and the formation of new companies. With a team that boasts deep expertise in drug development and strong relationships within academia and patient advocacy, Cydan accelerates therapies through various stages, including clinical, regulatory, and commercial development. By facilitating the creation of effective treatments, Cydan aims to improve the lives of patients and families affected by rare diseases.
Theraclone Sciences
Series B in 2013
Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.
Theraclone Sciences
Venture Round in 2011
Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.
Oncofactor
Series A in 2011
Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
Acylin Therapeutics
Series A in 2011
Acylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.
Groove Biopharma
Series A in 2010
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Theraclone Sciences
Venture Round in 2010
Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.
Metabolon
Series C in 2009
Metabolon develops metabolomics-based platforms and clinical diagnostic tests for early disease detection and precision medicine. It offers blood tests like QUANTOSE IR and QUANTOSE IGT, and Meta IMD for inherited metabolic disorders. The company serves various sectors including academia, biotech/pharmaceuticals, and precision medicine. It has strategic partnerships with major pharmaceutical companies and other industries.
Genocea Biosciences
Series A in 2009
Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.
BrainCells
Series B in 2008
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.
Cerulean Pharma
Series B in 2008
Cerulean Pharma Inc. is a privately-held biopharmaceutical company specializing in the development of innovative nanotechnology-based therapeutics, primarily targeting oncology, cardiovascular, autoimmune, and inflammatory diseases. The company focuses on creating nanoparticle-drug conjugates that aim to selectively target tumors, minimize toxicity, and facilitate drug combinations. Among its notable products is Ovaprene, a contraceptive designed to offer multiple weeks of protection without hormones, addressing needs in fertility and vaginal health. Cerulean Pharma boasts a distinguished management team and advisory board, comprising experts with extensive experience in product development and scientific advancements from leading organizations and institutions, including GlaxoSmithKline, Merck, and Harvard Medical School.
Allozyne, Inc. is a biopharmaceutical company focused on developing novel protein therapeutic product candidates aimed at treating autoimmune and inflammatory diseases, as well as cancer. Founded in 2004 and headquartered in Seattle, Washington, Allozyne is known for its lead product candidate, AZ01, which is currently in Phase 1b clinical trials for relapsing-remitting multiple sclerosis. The company is also advancing AZ17, a bispecific antibody targeting various autoimmune and inflammatory conditions, including Crohn's disease and multiple sclerosis, and AZ05, an antibody-drug conjugate designed for treating solid tumors. Additionally, Allozyne specializes in the development of technologies that enhance the efficacy, safety, and dosing of protein-based therapeutics, including peptides and antibodies. The company operates as a subsidiary of Poniard Pharmaceuticals, Inc.
Accelerator Corp.
Series C in 2007
Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.
Theraclone Sciences
Series B in 2007
Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.
Magen BioSciences
Series A in 2006
Magen BioSciences is a biotechnology company based in Waltham, Massachusetts, specializing in the development of pharmaceutical products aimed at enhancing human skin health. The company employs a science-driven methodology that is rooted in a comprehensive understanding of both normal and diseased skin biology. By leveraging this expertise, Magen BioSciences creates innovative solutions designed to improve the health and appearance of skin, addressing various dermatological needs.
Map Pharmaceuticals
Series C in 2006
Map Pharmaceuticals, Inc. is a development stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, which targets migraine relief. Additionally, the product portfolio features MAP0005 for the treatment of asthma and chronic obstructive pulmonary disease in adolescents and adults, as well as MAP0001, designed for pulmonary delivery of medications for Type 1 and Type 2 diabetes utilizing the Tempo inhaler. Map Pharmaceuticals is focused on improving treatment options for patients with various health conditions.
Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.
Integrated Diagnostics
Series A in 2005
Integrated Diagnostics Inc. is a company focused on developing laboratory-based blood diagnostic tools that facilitate the early diagnosis of complex diseases through non-invasive blood tests. Established in 2005 and headquartered in Seattle, Washington, the company specializes in products that monitor multiple molecular markers simultaneously, offering valuable insights for conditions such as lung cancer. One of its key offerings is Xpresys Lung, a molecular blood test designed to provide objective information for assessing pulmonary nodules. Integrated Diagnostics is committed to leveraging advanced technologies to create a pipeline of innovative diagnostic products aimed at enhancing disease management for conditions including cancer, diabetes, and Alzheimer's. The company operates under a strategic partnership with Agilent Technologies Inc. and has been functioning as a subsidiary of Biodesix, Inc. since 2018.
Accelerator Corp.
Venture Round in 2004
Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.
Metabolon
Series A in 2004
Metabolon develops metabolomics-based platforms and clinical diagnostic tests for early disease detection and precision medicine. It offers blood tests like QUANTOSE IR and QUANTOSE IGT, and Meta IMD for inherited metabolic disorders. The company serves various sectors including academia, biotech/pharmaceuticals, and precision medicine. It has strategic partnerships with major pharmaceutical companies and other industries.
Accelerator Corp.
Venture Round in 2003
Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers.
Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development.
Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
MacroGenics
Venture Round in 2002
MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment. Its pipeline includes Margetuximab targeting HER2-expressing tumors, Flotetuzumab for acute myeloid leukemia, and other immuno-oncology product candidates such as MGA012, MGD013, MGD019, and Enoblituzumab. The company also develops combination therapies like MGD009 with MGA012, and antibody drug conjugates like MGC018 targeting B7-H3.
Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.
Norak Biosciences
Series B in 2002
Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a
private biotechnology company. Norak is utilizing its proprietary Transfluor
technology to become a world leader in the discovery and development of drugs
that regulate G protein-coupled receptors.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers.
Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development.
Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
GoAhead Software, Inc. specializes in developing integrated middleware solutions tailored for the telecom, military, and aerospace sectors. Founded in 1993 and based in Bellevue, Washington, the company provides a range of products designed to enhance system management and reliability. Notable offerings include SelfReliant, which focuses on high availability and systems management, and the Application Ready Platform, which supports resource discovery, system model instantiation, and various integration tasks. Additionally, GoAhead develops WebServer, an open-source solution catering to embedded device developers, featuring support for active server pages, embedded JavaScript, and user management. The company's software is utilized across diverse projects, including wireless base station controllers and defense applications.